Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Supportive Care
Based on the FDA indication is fezolinetant (Veozah) in menopause induced hot flashes, is it also used for Aromatase Inhibitor induced hot flashes in the clinical setting?
And where are you offering it in the order of supportive care measures?
Related Questions
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
How do you consider the role of probiotics for mucositis mitigation in patients receiving head and neck radiotherapy?
How do you mitigate cognitive slowing in elderly patients with mCSPC receiving LHRH agonist therapy?
In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?
What, if any, resources exist with recommendations regarding the timing and toxicity of radiation in patients who have received or are currently on immunotherapy?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
How would you approach post-chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PD-L1 level?
For a patient with high-risk metastatic endometrial cancer treated with neoadjuvant chemotherapy followed by surgery, would you offer adjuvant therapy if there is evidence of residual disease?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?
What adjuvant therapy would you recommend for a postmenopausal female with a dedifferentiated endometrial cancer, extensive LVI but negative nodes, MSI-high (somatic) and >50% myometrial invasion?